<DOC>
	<DOCNO>NCT00527683</DOCNO>
	<brief_summary>The primary objective study assess efficacy vigabatrin treatment cocaine dependence , base twice-weekly qualitative urine toxicology cocaine . Based two prior unblinded human study 15 year animal study , 100 subject double- blind , randomize study design show vigabatrin treatment placebo , even non-hospitalized cocaine dependent individual ready access cocaine become cocaine abstinent self motivate stop cocaine habit . To accomplish , cocaine dependent subject randomly assign either placebo vigabatrin treatment group treat nine week period . The primary hypothesis compare placebo arm , vigabatrin treatment arm show significant increase number subject abstinent final 3 week study .</brief_summary>
	<brief_title>Double Blind Study Vigabatrin Treatment Cocaine Dependence</brief_title>
	<detailed_description />
	<mesh_term>Cocaine-Related Disorders</mesh_term>
	<mesh_term>Vigabatrin</mesh_term>
	<mesh_term>Cocaine</mesh_term>
	<criteria>In order participate study , subject must Be least 18 year age old 55 year age . Weigh 100 pound . Have DSMIV diagnosis cocaine dependence . Be seek treatment cocaine dependence . Have urine sample positive qualitative cocaine toxicology initial screening . Have ability understand , understood , provide write informed consent comply treatment protocol . Have history brief physical examination demonstrate clinically significant contraindication participate study , judgment admit physician Principal Investigator . Have normal , , necessary , correct visual acuity , visual field , normal fundoscopy finding In order participate study , subject must : Meet DSMIV criterion current dependence psychoactive substance cocaine , alcohol , nicotine , marijuana physiological dependence alcohol require medical detoxification . Have neurological psychiatric disorder : psychosis , bipolar illness , major depression , organic brain disease , dementia , disorder would require ongoing treatment would make study agent compliance difficult , history suicide attempt assess and/or current suicidal ideation/plan . Have serious medical illness potentially life threaten progressive medical illness addiction may compromise subject safety study conduct . Have history traumatic head injury . Be mandate court obtain treatment cocaine dependence . Have treat cocaine addiction , abstain cocaine use significant period , within 6 month precede screening . Be unable complete study protocol probable incarceration relocation clinical area . Have AIDS ( although AIDS exclusion criterion , positive antibody titer HIV ) . Have active syphilis treat refuse treatment syphilis Have history neuroleptic malignant syndrome . Have know suspected hypersensitivity vigabatrin GABAergic drug . Have receive drug know potential toxicity major organ system within 30 day prior study entry ( e.g. , isoniazid , methotrexate ) . Have participate experimental study within 4 week , participate clinical trial utilize vigabatrin . Be pregnant lactating . Have clinically significant abnormal laboratory value . Have electroconvulsive therapy 3 month precede screening . Have opiatesubstitutes ( methadone , LAAM , buprenorphine ) within 2 month precede screening . Have history i.v . cocaine ( psychoactive drug ) use within 2 month precede screening . Have current past history seizure disorder , include alcohol stimulant related seizure , febrile seizure , significant family history idiopathic seizure disorder . Have visual field defect , factor predispose visual field defect , include glaucoma , severe myopia , retinal disorder , cataract , diabetes uncontrolled hypertension . Have illness , condition , use medication , opinion Principal Investigator admit physician , would preclude safe successful completion study . Be use vigabatrin medication could interact adversely vigabatrin administration , base long time interval A B : A ) Five halflives medication active metabolite ( ) , whichever longer ; B ) Two week . Be lactose intolerant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>vigabatrin</keyword>
	<keyword>GVG</keyword>
	<keyword>addiction</keyword>
	<keyword>treatment</keyword>
	<keyword>cocaine dependence</keyword>
</DOC>